
In comments submitted Saturday, AHA generally supports the Centers for Medicare & Medicaid Servicesâ initial guidance implementing inflation rebates for certain single source drugs and biosimilar biological products covered by Medicare Part B, but recommends changes to prevent incentivizing drug shortages and burdening 340B hospitals.